Education
About Us
Working with TipRanks
Follow Us
IO Biotech (IOBT)
NASDAQ:IOBT
IOBT Stock Chart & Stats
$0.69
-$0.03(-3.11%)
At close: 4:00 PM EST
$0.69
-$0.03(-3.11%)
Day’s Range― - ―
52-Week Range$0.32 - $2.79
Previous CloseN/A
Volume57.25K
Average Volume (3M)837.13K
Market Cap
$49.64M
Enterprise Value$11.76M
Total Cash (Recent Filing)$30.66M
Total Debt (Recent Filing)$1.46M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding71,948,845
10 Day Avg. Volume918,240
30 Day Avg. Volume837,126
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.29
Price to Sales (P/S)0.00
P/FCF Ratio-0.74
Enterprise Value/Market Cap0.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-12.92
Enterprise Value/Ebitda-0.13
Forecast
1Y Price Target
$1.70Price Target Upside146.38% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-1.09
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsThe trial demonstrated a median PFS of 19.4 months in combination therapy versus 11.0 months with pembrolizumab alone, showing an impressive 8+ month benefit in median PFS.
Regulatory PathwayDecember meeting with FDA could help pave path forward for Cylembio.
Strategic PlanningThe management intends to file for approval by the end of the year and is seeking Priority Review, indicating a proactive strategy despite challenges.
Bears Say
Financial ConstraintsEnded 3Q25 with $31M in cash which supports operations through 1Q26; remain Equal-weight given uncertainly on path forward and limited cash.
Operational RestructuringAnnounces restructuring including a 50% head count reduction.
Regulatory ChallengesFDA recommended against a BLA filing on prior Ph3 data which showed robust trends but narrowly missed statistical significance.
IO Biotech News
IOBT FAQ
What was IO Biotech’s price range in the past 12 months?
IO Biotech lowest stock price was $0.32 and its highest was $2.79 in the past 12 months.
What is IO Biotech’s market cap?
IO Biotech’s market cap is $49.64M.
When is IO Biotech’s upcoming earnings report date?
IO Biotech’s upcoming earnings report date is May 19, 2026 which is in 151 days.
How were IO Biotech’s earnings last quarter?
IO Biotech released its earnings results on Nov 14, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.324 by $0.194.
Is IO Biotech overvalued?
According to Wall Street analysts IO Biotech’s price is currently Undervalued.
Does IO Biotech pay dividends?
IO Biotech does not currently pay dividends.
What is IO Biotech’s EPS estimate?
IO Biotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IO Biotech have?
IO Biotech has 71,948,845 shares outstanding.
What happened to IO Biotech’s price movement after its last earnings report?
IO Biotech reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.324. Following the earnings report the stock price went up 2.469%.
Which hedge fund is a major shareholder of IO Biotech?
Currently, no hedge funds are holding shares in IOBT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
IO Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.70 (146.38% Upside)
$1.70 (146.38% Upside)
Blogger Sentiment
Bullish
IOBT Sentiment 66%
Sector Average 68%
Sector Average 68%
Crowd Wisdom
Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 3.6%
Last 30 Days ▲ 3.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.32%
12-Months-Change
Fundamentals
Return on Equity
-240.48%
Trailing 12-Months
Asset Growth
-55.58%
Trailing 12-Months
Company Description
IO Biotech
IO Biotech (IOBT) is a biotechnology company focused on the development of immune-modulating cancer therapies. The company leverages its proprietary T-win technology platform to create novel immune therapies intended to treat various types of cancer by activating the immune system against tumor cells. IO Biotech operates within the pharmaceutical and biotechnology sector, working towards innovative solutions to improve cancer treatment outcomes.
IOBT Stock 12 Month Forecast
Average Price Target
$1.70
▲(146.38% Upside)
Technical Analysis
Ownership Overview
19.72% Insiders
0.15% Mutual Funds
5.95% Other Institutional Investors
74.18% Public Companies and Individual Investors
Options Prices
Currently, No data available
---